Mild uncoupling of oxidative phosphorylation is an intrinsic property of all mitochondria, allowing for adjustments in cellular energy metabolism to maintain metabolic homeostasis. Small molecule uncouplers have been extensively studied for their potential to increase metabolic rate, and recent research has focused on developing safe and effective mitochondrial uncoupling agents for the treatment of obesity and cardiometabolic syndrome (CMS). Here, we provide a brief overview of CMS and cover the recent mechanisms by which chemical uncouplers regulate CMS-associated risk-factors and comorbidities, including dyslipidemia, insulin resistance, steatotic liver disease, type 2 diabetes, and atherosclerosis. Additionally, we review the current landscape of uncoupling agents, focusing on repurposed FDA-approved drugs and compounds in advanced preclinical or early-stage clinical development. Lastly, we discuss recent molecular insights by which chemical uncouplers enhance cellular energy expenditure, highlighting their potential as a new addition to the current CMS drug landscape, and outline several limitations that need to be addressed before these agents can successfully be introduced into clinical practice.
-
Cover Image
Cover Image
The cover of this issue of the Biochemical Journal features confocal imaging of internalisation of the APJR-EGFP receptor transiently expressed in HEK293T cells, read more in "Divergent roles of DRY and NPxxY motifs in selective activation of downstream signalling by the apelin receptor" by Aradhyam and colleagues on pages 1707–1722.
Biochemical basis and therapeutic potential of mitochondrial uncoupling in cardiometabolic syndrome
Bernardo Gindri dos Santos, Niki F. Brisnovali, Leigh Goedeke; Biochemical basis and therapeutic potential of mitochondrial uncoupling in cardiometabolic syndrome. Biochem J 4 December 2024; 481 (23): 1831–1854. doi: https://doi.org/10.1042/BCJ20240005
Download citation file:
Sign in
Sign in to your personal account
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
View past webinars > |